Crisis resilience in persons with MS

Dr Yvonne Learmonth

Murdoch University, WA

January 2021

specialisation: Social And Applied Research

focus area: Better treatments

funding type: Project

project type: Investigator Led Research

Summary

The Australian bushfires of 2019/2020, closely followed by the COVID-19 pandemic, have brought crisis care capabilities for people living with MS to the forefront. Currently, there is scarce research exploring the impact of natural disasters and pandemics in the MS population. More generally, research has shown that individuals living with disability may be up to four times more likely to sustain injuries or death in disaster circumstances compared to the general population. This is mainly due to impairments in areas such as mobility, cognition and communication. At present there are no formal recommendations in place to guide management of people living with MS in times of crises.

Associate Professor Yvonne Learmonth and her team will explore the prevalence and impact of the 2019/2020 bushfires and pandemic on the healthcare of people living with MS in Australia. They will perform interviews and surveys to understand the experiences and responses of people affected. Analysing this information will provide the foundations for developing a toolkit for healthcare-based disaster management for people with MS in the future. It is also anticipated that this toolkit will also be useful for people living with disability from other conditions, and that it can be refined to their specific needs. This would broaden the impact of this research across the wider community.

Progress

Associate Professor Learmonth and her team collaborated with the Australian Red Cross and co-designed a Crisis Toolkit in partnership with the MS Community. This Crisis Toolkit was tested for its usefulness and made freely available at the start of the 2024/2025 summer. The Crisis Toolkit is designed to help people with MS better prepare for a range of crises, including maintaining health behaviours, accessing healthcare and connecting with relevant services and support networks.

The Toolkit was tested by 14 people with MS who have moderate to severe disability, lived in disaster-prone areas, and did not have a current disaster plan. Most participants found the Crisis Toolkit useful and reported increased and sustained confidence in knowing what to do in a crisis. They also reported improvements in resilience and disaster preparedness, and a reduction in stress, that continued over three months. MS nurses supported seven participants to complete their disaster plans.

Having MS nurses assist with implementing the Crisis Toolkit was helpful, though more support may be needed for larger trials. Further research is needed to evaluate how well the Toolkit works in other groups and to understand its long-term benefits. The MS nurses identified that existing relationships with clients and knowledge of their medical needs helped make the Toolkit easier to complete.

The Crisis Toolkit has the potential to deliver economic and social benefits by reducing the impact of crisis events and improving outcomes for people with MS during and after crisis events.

publications

  • Learmonth Y.C., Bhoyroo R., Gibbs L., Kermode A., Walker D., Marck C.H. Multiple Sclerosis and COVID-19: Health and healthcare access, health information and consumer co-created strategies for future access at times of crisis (2024) Multiple Sclerosis and Related Disorders, 87,
  • Learmonth Y.C., Assunta H., Skeffington P., Diana W., Kermode A.G., Marck C.H. Healthcare complexities during community crises: Recommendation for access to healthcare for Australians with multiple sclerosis Mult Scler Relat Disord 2023 Mar;71:104531
  • Marck C.H., Galna B., van der Mei I.A.F., Laslett L.L., Tan J., Gibbs L., Kermode A.G., Walker D.I., Learmonth Y.C. Crisis preparation for people with multiple sclerosis in Australia: A cross-sectional survey of needs (2024) International Journal of Disaster Risk Reduction, 109,
  • Learmonth YC, Hunter A, Gibbs L, Walker D, Kermode AG, Marck CH. The impact of the Australian Black Summer Bushfires and the COVID-19 pandemic on wellbeing in persons with multiple sclerosis; preparation for future and ongoing crises. Disabil Rehabil. 2022 Feb 15:1-14.
  • Marck CH, Hunter A, Heritage B, Gibbs L, Kermode AG, Walker DI, Learmonth YC. The effect of the Australian bushfires and the COVID-19 pandemic on health behaviours in people with multiple sclerosis. Mult Scler Relat Disord. 2021 Aug;53:103042.
  • Learmonth, Y. C., Galna, B., Laslett, L. L., van der Mei, I., & Marck, C. H. (2023). Improving telehealth for persons with multiple sclerosis – a cross-sectional study from the Australian MS longitudinal study. Disabil Rehabil, 1-8. https://doi.org/10.1080/09638288.2023.2289594
  • Pedullà L., …., Learmonth Y., et al Physical Activity in Multiple Sclerosis: Meeting the Guidelines at the Time of the COVID-19 Pandemic (2023) Journal of Neurologic Physical Therapy, 47 (2), pp. 112 – 121
  • Jonsdottir J., …Learmonth Y., et al Changes in physiotherapy services and use of technology for people with multiple sclerosis during the COVID-19 pandemic (2023) Multiple Sclerosis and Related Disorders, 71, art. no. 104520
  • van der Linden M.L., …Learmonth Y.C. Changes in physical activity participation during the COVID-19 pandemic in people with multiple sclerosis: An international survey study (2023) Annals of Physical and Rehabilitation Medicine, 66 (7), art. no. 101798

Updated 31 March 2025

lead investigator

co-investigator

Dr Claudia Marck
Dr Brody Heritage
Dr Lisa Gibbs
Dr Ingrid van der Mei
Dr Petra Skeffington
Dr Allan Kermode
Professor Diana Walker

total funding

$230,000

start year

2021

duration

3 years

STATUS

Current project

Stages of the research process

Fundamental laboratory Research

Laboratory research that investigates scientific theories behind the possible causes, disease progression, ways to diagnose and better treat MS.

Lab to clinic timeline

10+ years

Translational Research

Research that builds on fundamental scientific research to develop new therapies, medical procedures or diagnostics and advances it closer to the clinic.

Lab to clinic timeline

5+ years

Clinical Studies and Clinical Trials

Clinical research is the culmination of fundamental and translational research turning those research discoveries into treatments and interventions for people with MS.

Lab to clinic timeline

3+ years

Read More
Dr Phu Hoangdr-mastura-monif

Newsletter subscription

  • This field is for validation purposes and should be left unchanged.

Crisis resilience in persons with MS